Cell and Gene Therapy Manufacturing QC Market to Grow at 6.85% CAGR thorugh 2029

Rise in prevalence of cancer & cardiovascular diseases and growth in pharmaceutical research & development is expected to drive the Global Cell and Gene Therapy Manufacturing QC Market growth in the forecast period, 2025-2029.

According to TechSci Research report, “Cell and Gene Therapy Manufacturing QC Market – Global Industry Size, Share, Trends, Competition, Forecast & Opportunities, 2029F”, the Global Cell and Gene Therapy Manufacturing QC Market stood at USD 1.04 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 6.85% through 2029. The exponential growth of the Global Cell and Gene Therapy Manufacturing QC Market is propelled by a confluence of factors, including significant advancements in medical biotechnology, a rise in chronic disease prevalence, and escalating demand for personalized medicine. Biopharmaceutical companies' substantial investments in R&D, coupled with regulatory support streamlining approvals for cell and gene therapies, contribute to market expansion.

The market is witnessing unprecedented growth, fueled by increasing demand for personalized medicine and a surge in clinical trials focused on cutting-edge cell and gene therapies. Innovations in genomics and cell biology are revolutionizing the landscape, driving the development of novel therapies with transformative potential. Researchers are pushing boundaries in medicine, exploring advanced techniques such as gene editing and tissue engineering, unlocking new treatment avenues and possibilities.

Alongside these breakthroughs, ensuring the safety, efficacy, and long-term viability of these therapies remains paramount. Robust quality control measures are essential to mitigate risks and ensure the delivery of safe and effective treatments. Specialized services and assays play a critical role in upholding the high standards necessary for the success and widespread adoption of these therapies. As the industry advances, there is increasing focus on stringent quality control practices and regulatory compliance. Comprehensive, specialized services are crucial to meet the evolving demands of this dynamic sector. By embracing advanced quality control processes and regulatory practices, the industry can thrive, ushering in an era of innovative therapies with the potential to revolutionize global healthcare.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Cell and Gene Therapy Manufacturing QC Market”

The Global Cell and Gene Therapy Manufacturing QC Market is segmented into therapy type, offering, process, technology, application, regional distribution, and company.

Based on technology, the Polymerase Chain Reaction (PCR) is dominating the Global Cell and Gene Therapy Manufacturing QC (Quality Control) Market. Several key factors underscore the efficacy, versatility, and reliability of polymerase chain reaction (PCR) in ensuring the quality and safety of cell and gene therapy products. PCR is renowned for its exceptional sensitivity and specificity, allowing for the detection and quantification of nucleic acids with unparalleled accuracy. In the realm of cell and gene therapy manufacturing, where precise measurement of target DNA sequences is crucial, PCR's capacity to amplify and detect specific genetic sequences makes it an indispensable tool for quality control processes. PCR offers rapid turnaround times, facilitating swift and efficient detection of contaminants, such as adventitious agents or residual DNA, in cell and gene therapy products. This rapid detection capability is vital for prompt decision-making during manufacturing processes, ensuring that only products meeting stringent quality standards proceed to subsequent stages of development or clinical trials. PCR techniques have evolved to encompass a diverse range of applications, including quantitative PCR (qPCR), reverse transcription PCR (RT-PCR), digital PCR (dPCR), and multiplex PCR. These variations of PCR assays provide researchers and manufacturers with versatile tools for various QC applications, such as assessing the purity, identity, potency, and integrity of cell and gene therapy products.

Based on region, Asia Pacific has emerged as the fastest growing region of the global market for cell and gene therapy manufacturing quality control. The biopharmaceutical industry in the Asia Pacific region has experienced notable growth, marked by increased investment in research and development (R&D) activities focused on cell and gene therapies. This expansion presents opportunities for the implementation of quality control (QC) solutions to guarantee the safety, effectiveness, and quality of these cutting-edge therapies. The Asia Pacific region has emerged as a central location for conducting clinical trials and obtaining market approvals for cell and gene therapies. With a sizable patient population and growing demand for innovative treatments, pharmaceutical companies are actively pursuing clinical trials and regulatory approval for these therapies within the region. There is a growing demand for QC solutions to ensure adherence to regulatory standards and facilitate market entry. The escalating healthcare expenditure and awareness of advanced therapies among healthcare professionals and patients in the Asia Pacific region are driving the demand for cell and gene therapies. As these therapies gain wider acceptance, there is an increasing imperative for stringent QC measures to uphold product quality and safeguard patient well-being.

Major companies operating in Global Cell and Gene Therapy Manufacturing QC Market are:

• Bio-Techne Corporation
• Biomerieux SA
• F. Hoffmann-La Roche Ltd
• Lonza Group Ltd. 
• Miltenyi Biotec India Pvt Ltd. 
• Sartorius AG
• Thermo Fisher Scientific Inc.
• AGC Inc. 
• Charles River Laboratories International, Inc.
• Merck KGaA

Download Free Sample Report

Customers can also request for 10% free customization on this report

“The Cell and Gene Therapy Manufacturing QC (Quality Control) Market is set for significant growth due to evolving biotechnology and healthcare trends. Advancements in biotechnology drive the innovation of cell and gene therapies, while the rising demand for personalized medicine emphasizes the need for stringent quality control. This market expansion is fueled by transformative trends and technological advancements, reshaping therapy development, manufacturing, and delivery processes. A primary driver of this growth is the evolution of regulatory frameworks governing advanced therapy development and manufacturing. Regulatory agencies like the U.S. FDA and the European Medicines Agency continuously refine guidelines to ensure therapy safety, efficacy, and quality. As regulations adapt to address the complexities of advanced therapies, manufacturers are compelled to implement rigorous quality control measures throughout the manufacturing process. This adaptation ensures compliance and maintains the integrity of therapies entering the market”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Cell and Gene Therapy Manufacturing QC Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy Type (Cell Therapy, Gene Therapy), By Offering (Instruments, Consumables, Others), By Process (Raw Material Preparation, Upstream Processing, Downstream Processing, Packaging), By Technology (Polymerase Chain Reaction (PCR), Flow Cytometry, Limulus Amebocyte Lysate (LAL), Enzyme-Linked Immunosorbent Assay (ELISA), Chromatography, Mass Spectrometry, Western Blotting, Next-Generation Sequencing (NGS), Electrophoresis, Others), By Application (Safety Testing, Potency Testing, Identity Testing, Stability and Genetic Fidelity Testing, Others), By Region and Competition, 2019-2029F”, has evaluated the future growth potential of Global Cell and Gene Therapy Manufacturing QC Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Cell and Gene Therapy Manufacturing QC Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com